Transcode Therapeutics Reports $19.5 Million Net Loss and Increased R&D Expenses in Latest 10-Q

Transcode Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of approximately $19.5 million, a substantial increase from the $12.1 million loss reported in the same period last year. This increase in losses is attributed to heightened research and development expenses, which surged to $15.5 million from $2.2 million, primarily due to costs associated with the acquisition of the Unleash program and increased clinical trial expenditures. General and administrative expenses also rose to $2.2 million, up from $951,000, reflecting higher professional service fees related to the acquisition and licensing activities.

In terms of operational changes, Transcode completed the acquisition of ABCJ, LLC, which owns Polynoma, LLC, on October 8, 2025. This acquisition involved the issuance of Series A Non-Voting Convertible Preferred Stock and was part of a broader strategy to enhance its oncology pipeline. The company also entered into a licensing agreement with Unleash Immuno Oncolytics, granting it rights to develop a pre-clinical candidate program involving genetically-engineered adenoviruses. This agreement included the issuance of Series C Non-Voting Convertible Preferred Stock, which is pending stockholder approval for conversion into common stock.

As of March 31, 2026, Transcode's cash position stood at approximately $12.8 million, down from $17.8 million at the end of 2025. The company anticipates that this cash, along with expected reimbursements from DEFJ, will be sufficient to fund operations through the end of 2026. However, the company has indicated a need for additional capital to support ongoing research and development activities, particularly as it advances clinical trials for its lead candidate, TTX-MC138, and other therapeutic programs.

The company has not generated any revenue to date and continues to rely on equity financing and grants to fund its operations. It has received approximately $95.8 million in net proceeds since its IPO in July 2021. The outlook remains cautious, with management acknowledging the risks associated with drug development and the need for substantial additional funding to continue operations and pursue its business strategy. The company is also subject to various market risks, including potential impacts from geopolitical events and economic conditions, which could affect its operations and financial performance.